Abstract
CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CROSS-RESISTANT PLATINUM ANALOGS
Michelle Martinez-Rivera, B.S.
Advisory Professor: Zahid H. Siddik, Ph.D.
Cisplatin (cis-Pt), an anticancer platinum (Pt) drug, is used widely in the treatment of several malignancies, such as ovarian cancer. This Pt compound induces DNA damage, which results in p53 activation through post-translational modifications, mainly phosphorylation, culminating in execution of programmed cell-death. However, despite initial therapeutic response to cis-Pt, clinical resistance to this drug emerges leading to disease progression. Pt-resistance phenotypes have been associated with dysfunction in the p53 signaling pathway. Therefore, an effort to understand molecular mechanisms that prevent p53 activity and induce cis-Pt resistance becomes vital for designing Pt-based drugs able to re-activate p53 and improve clinical management of ovarian cancer patients. To investigate the mechanism responsible for p53 inactivation, an ovarian tumor panel composed of cis-Pt sensitive (A2780) and resistant (2780CP/Cl-16, OVCAR-10, HEY and OVCA 433) cell lines was established, with two (2780CP/Cl-16 and OVCAR-10) harboring missense mutant p53. The data obtained from these cancer cell lines have identified a correlation between cis-Pt resistance, regardless of p53 status (wild-type vs. mutant), and lack of phosphorylation of p53 at Ser20 after cis-Pt treatment. Cis-Pt resistant cell lines expressed low levels of Chk2, a kinase responsible to phosphorylate p53 at Ser20, as a common feature. It was confirmed, through the generation of Chk2 knock-out clones from A2780 cells using the CRISPR/Cas9 system, that Chk2 is essential for cis-Pt to mediate phosphorylation of p53 at Ser20 and induce p53 transcriptional activity. As validation of its critical role, Chk2 knock-out in these cells leads to cis-Pt resistance. However, cis-Pt resistance was circumvented by a number of cis-Pt analogs. In this regard, oxaliplatin (oxali-Pt), a non-cross-resistant Pt analog currently used in colon cancer but not ovarian cancer, was the most effective. Interestingly, the mechanism for oxali-Pt involved restoration of p53 phosphorylation at Ser20 through a Chk2 independent pathway. RPPA analysis has identified the MAPK pathway as a possible target of activation by oxali-Pt to phosphorylate p53 at Ser20. Systematic studies using targeted inhibitors have identified MEK1/2, but not ERK1/2, as a novel biomarker important to mediate p53-Ser20 phosphorylation by oxali-Pt. Overall, the findings gathered in this research project have revealed Ser20 of p53 as a key site that induces cis-Pt resistance when its phosphorylation is not induced by cis-Pt due to loss of Chk2, whereas its phosphorylation by oxali-Pt via MEK1/2 leads to circumvention of this resistance. This knowledge may lead to repurposing oxali-Pt in ovarian cancer and improve survival of cancer patients.
","abstract_html":"<p><strong>Abstract</strong></p> <p><strong>CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CROSS-RESISTANT PLATINUM ANALOGS</strong></p> <p><strong>Michelle Martinez-Rivera, B.S.</strong></p> <p><strong>Advisory Professor: Zahid H. Siddik, Ph.D.</strong></p> <p>Cisplatin (cis-Pt), an anticancer platinum (Pt) drug, is used widely in the treatment of several malignancies, such as ovarian cancer. This Pt compound induces DNA damage, which results in p53 activation through post-translational modifications, mainly phosphorylation, culminating in execution of programmed cell-death. However, despite initial therapeutic response to cis-Pt, clinical resistance to this drug emerges leading to disease progression. Pt-resistance phenotypes have been associated with dysfunction in the p53 signaling pathway. Therefore, an effort to understand molecular mechanisms that prevent p53 activity and induce cis-Pt resistance becomes vital for designing Pt-based drugs able to re-activate p53 and improve clinical management of ovarian cancer patients. To investigate the mechanism responsible for p53 inactivation, an ovarian tumor panel composed of cis-Pt sensitive (A2780) and resistant (2780CP/Cl-16, OVCAR-10, HEY and OVCA 433) cell lines was established, with two (2780CP/Cl-16 and OVCAR-10) harboring missense mutant p53. The data obtained from these cancer cell lines have identified a correlation between cis-Pt resistance, regardless of p53 status (wild-type vs. mutant), and lack of phosphorylation of p53 at Ser20 after cis-Pt treatment. Cis-Pt resistant cell lines expressed low levels of Chk2, a kinase responsible to phosphorylate p53 at Ser20, as a common feature. It was confirmed, through the generation of Chk2 knock-out clones from A2780 cells using the CRISPR/Cas9 system, that Chk2 is essential for cis-Pt to mediate phosphorylation of p53 at Ser20 and induce p53 transcriptional activity. As validation of its critical role, Chk2 knock-out in these cells leads to cis-Pt resistance. However, cis-Pt resistance was circumvented by a number of cis-Pt analogs. In this regard, oxaliplatin (oxali-Pt), a non-cross-resistant Pt analog currently used in colon cancer but not ovarian cancer, was the most effective. Interestingly, the mechanism for oxali-Pt involved restoration of p53 phosphorylation at Ser20 through a Chk2 independent pathway. RPPA analysis has identified the MAPK pathway as a possible target of activation by oxali-Pt to phosphorylate p53 at Ser20. Systematic studies using targeted inhibitors have identified MEK1/2, but not ERK1/2, as a novel biomarker important to mediate p53-Ser20 phosphorylation by oxali-Pt. Overall, the findings gathered in this research project have revealed Ser20 of p53 as a key site that induces cis-Pt resistance when its phosphorylation is not induced by cis-Pt due to loss of Chk2, whereas its phosphorylation by oxali-Pt via MEK1/2 leads to circumvention of this resistance. This knowledge may lead to repurposing oxali-Pt in ovarian cancer and improve survival of cancer patients.</p>","abstract_has_math":false,"creators":["Martinez-Rivera, Michelle"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation (PhD)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Zahid H. Siddik, Ph.D.","Gary Gallick, Ph.D.","Peng Huang, MD, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-08-01T07:00:00Z","date_published":"2016-08-01T07:00:00Z","updated_at":"2026-07-24T05:50:31Z","subjects":["cisplatin","platinum resistance","oxaliplatin","p53","ovarian cancer","Chk2","MEK1/2","Inorganic Chemicals","Medicine and Health Sciences","Molecular Biology","Therapeutics"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/694","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Zahid H. Siddik, Ph.D.","Gary Gallick, Ph.D.","Peng Huang, MD, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Martinez-Rivera, Michelle"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2017-08-15T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation (PhD)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cisplatin","platinum resistance","oxaliplatin","p53","ovarian cancer","Chk2","MEK1/2","Inorganic Chemicals","Medicine and Health Sciences","Molecular Biology","Therapeutics"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/694"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Abstract
CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CROSS-RESISTANT PLATINUM ANALOGS
Michelle Martinez-Rivera, B.S.
Advisory Professor: Zahid H. Siddik, Ph.D.
Cisplatin (cis-Pt), an anticancer platinum (Pt) drug, is used widely in the treatment of several malignancies, such as ovarian cancer. This Pt compound induces DNA damage, which results in p53 activation through post-translational modifications, mainly phosphorylation, culminating in execution of programmed cell-death. However, despite initial therapeutic response to cis-Pt, clinical resistance to this drug emerges leading to disease progression. Pt-resistance phenotypes have been associated with dysfunction in the p53 signaling pathway. Therefore, an effort to understand molecular mechanisms that prevent p53 activity and induce cis-Pt resistance becomes vital for designing Pt-based drugs able to re-activate p53 and improve clinical management of ovarian cancer patients. To investigate the mechanism responsible for p53 inactivation, an ovarian tumor panel composed of cis-Pt sensitive (A2780) and resistant (2780CP/Cl-16, OVCAR-10, HEY and OVCA 433) cell lines was established, with two (2780CP/Cl-16 and OVCAR-10) harboring missense mutant p53. The data obtained from these cancer cell lines have identified a correlation between cis-Pt resistance, regardless of p53 status (wild-type vs. mutant), and lack of phosphorylation of p53 at Ser20 after cis-Pt treatment. Cis-Pt resistant cell lines expressed low levels of Chk2, a kinase responsible to phosphorylate p53 at Ser20, as a common feature. It was confirmed, through the generation of Chk2 knock-out clones from A2780 cells using the CRISPR/Cas9 system, that Chk2 is essential for cis-Pt to mediate phosphorylation of p53 at Ser20 and induce p53 transcriptional activity. As validation of its critical role, Chk2 knock-out in these cells leads to cis-Pt resistance. However, cis-Pt resistance was circumvented by a number of cis-Pt analogs. In this regard, oxaliplatin (oxali-Pt), a non-cross-resistant Pt analog currently used in colon cancer but not ovarian cancer, was the most effective. Interestingly, the mechanism for oxali-Pt involved restoration of p53 phosphorylation at Ser20 through a Chk2 independent pathway. RPPA analysis has identified the MAPK pathway as a possible target of activation by oxali-Pt to phosphorylate p53 at Ser20. Systematic studies using targeted inhibitors have identified MEK1/2, but not ERK1/2, as a novel biomarker important to mediate p53-Ser20 phosphorylation by oxali-Pt. Overall, the findings gathered in this research project have revealed Ser20 of p53 as a key site that induces cis-Pt resistance when its phosphorylation is not induced by cis-Pt due to loss of Chk2, whereas its phosphorylation by oxali-Pt via MEK1/2 leads to circumvention of this resistance. This knowledge may lead to repurposing oxali-Pt in ovarian cancer and improve survival of cancer patients.
"]},{"key":"dc:title","label":"Title","values":["Circumventing Cisplatin Resistance In Ovarian Cancers Through Reactivation of P53 By Non-Cross-Resistant Platinum Analogs"]}]}],"canonical_facts":{"dc:contributor":["Zahid H. Siddik, Ph.D.","Gary Gallick, Ph.D.","Peng Huang, MD, Ph.D."],"dc:creator":["Martinez-Rivera, Michelle"],"dc:date.available":["2017-08-15T07:00:00Z"],"dc:description.abstract":["Abstract
CIRCUMVENTING CISPLATIN RESISTANCE IN OVARIAN CANCERS THROUGH REACTIVATION OF P53 BY NON-CROSS-RESISTANT PLATINUM ANALOGS
Michelle Martinez-Rivera, B.S.
Advisory Professor: Zahid H. Siddik, Ph.D.
Cisplatin (cis-Pt), an anticancer platinum (Pt) drug, is used widely in the treatment of several malignancies, such as ovarian cancer. This Pt compound induces DNA damage, which results in p53 activation through post-translational modifications, mainly phosphorylation, culminating in execution of programmed cell-death. However, despite initial therapeutic response to cis-Pt, clinical resistance to this drug emerges leading to disease progression. Pt-resistance phenotypes have been associated with dysfunction in the p53 signaling pathway. Therefore, an effort to understand molecular mechanisms that prevent p53 activity and induce cis-Pt resistance becomes vital for designing Pt-based drugs able to re-activate p53 and improve clinical management of ovarian cancer patients. To investigate the mechanism responsible for p53 inactivation, an ovarian tumor panel composed of cis-Pt sensitive (A2780) and resistant (2780CP/Cl-16, OVCAR-10, HEY and OVCA 433) cell lines was established, with two (2780CP/Cl-16 and OVCAR-10) harboring missense mutant p53. The data obtained from these cancer cell lines have identified a correlation between cis-Pt resistance, regardless of p53 status (wild-type vs. mutant), and lack of phosphorylation of p53 at Ser20 after cis-Pt treatment. Cis-Pt resistant cell lines expressed low levels of Chk2, a kinase responsible to phosphorylate p53 at Ser20, as a common feature. It was confirmed, through the generation of Chk2 knock-out clones from A2780 cells using the CRISPR/Cas9 system, that Chk2 is essential for cis-Pt to mediate phosphorylation of p53 at Ser20 and induce p53 transcriptional activity. As validation of its critical role, Chk2 knock-out in these cells leads to cis-Pt resistance. However, cis-Pt resistance was circumvented by a number of cis-Pt analogs. In this regard, oxaliplatin (oxali-Pt), a non-cross-resistant Pt analog currently used in colon cancer but not ovarian cancer, was the most effective. Interestingly, the mechanism for oxali-Pt involved restoration of p53 phosphorylation at Ser20 through a Chk2 independent pathway. RPPA analysis has identified the MAPK pathway as a possible target of activation by oxali-Pt to phosphorylate p53 at Ser20. Systematic studies using targeted inhibitors have identified MEK1/2, but not ERK1/2, as a novel biomarker important to mediate p53-Ser20 phosphorylation by oxali-Pt. Overall, the findings gathered in this research project have revealed Ser20 of p53 as a key site that induces cis-Pt resistance when its phosphorylation is not induced by cis-Pt due to loss of Chk2, whereas its phosphorylation by oxali-Pt via MEK1/2 leads to circumvention of this resistance. This knowledge may lead to repurposing oxali-Pt in ovarian cancer and improve survival of cancer patients.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/694"],"dc:subject":["cisplatin","platinum resistance","oxaliplatin","p53","ovarian cancer","Chk2","MEK1/2","Inorganic Chemicals","Medicine and Health Sciences","Molecular Biology","Therapeutics"],"dc:title":["Circumventing Cisplatin Resistance In Ovarian Cancers Through Reactivation of P53 By Non-Cross-Resistant Platinum Analogs"],"thesis:degree_level":["Dissertation (PhD)"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:50:31Z"}